WEEKLY WRAP-UP

07TH SEPTEMBER - 11TH SEPTEMBER 2026

HIGHLIGHTS OF THE WEEK 07 Sept 2026-11 Sept 2026

DOMESTIC:

- Maruti Suzuki bets on premium hatchbacks as demand outpaces industry
- Bayer bets big on climate-resilient crops
- HUL bets on cost cuts, brand push to revive its growth: MD
- TCS's HyperVault to build 1GW AI data centre in Telangana
- Hyundai Motor India expects 30% sales to come from rural markets in 3-4 years: MD & CEO
- NMDC to start commercial coal production next quarter; eyes 1MT dry fuel sale in FY27: Chairman
- RVNL receives Rs903cr LoA from SJVN Thermal for buxar siding
- Anupam Rasayan secures chemical supply contract with US industrial major
- Lemon Tree Hotels announces twin signings in Bodhgaya, adding 145 rooms to Bihar portfolio
- Siemens Energy India advances cleaner high-voltage grid infrastructure
- GE Vernova T&D emerges lowest bidder for 6GW renewable power transmission project
- Novartis India buys Minipress brands from Pfizer for Rs1,250cr
- Adani Power wins GVK Energy resolution plan for 330MW hydro plant
- Suzlon has secured a maiden 200MW wind energy order from Ayana Renewable Power
- Biocon secures 10-year supply contract for Pertuzumab in Brazil
- Enviro Infra bags Rs190cr wind power project order from Tata Power Renewable Energy
- Fermenta Biotech signs exclusive licence with VIT for Vitamin B12 tech
- Adani among top applicants for Centre's Rs37,500cr coal gasification scheme
- Nalco ties up with EGA for 0.5MTPA smelter expansion
- Bank of Baroda to divest upto 35% of holding in NSE through OFS
- HCLTech launches Rs185cr advanced semiconductor lab in Bengaluru
- L&T secures upto Rs5,000cr offshore order for west coast energy projects
- Adani plans USD2.5bn refinancing in India's biggest offshore loan this year
- Axis Bank plans 32-storey HQ, may split 3,000 staff across Mumbai
- Marico bets big on premiumisation, targets 50% portfolio share by FY30
- Wipro, CrowdStrike launch CISO Command Centre for enterprise cybersecurity
- Sigma Advanced Systems begins production at Sri City Aerospace facility
- Ola Electric spent Rs229cr as 3W launch slips

ECONOMY:

- RBI uses currency swaps to cut USD115bn cash surplus
- FPIs sell USD1.6bn stocks in 5 trading sessions
- RBI launches inflation, consumer confidence surveys ahead of October MPC meeting

INDUSTRY:

- FDI may be allowed in more commercial crops
- Paint manufacturers expect healthy FY27 demand despite price increase
- India's office REIT operational area surges 74% y-o-y in H1 2026: Report

HIGHLIGHTS OF THE WEEK 07 Sept 2026-11 Sept 2026

COVERAGE NEWS:

Texmaco Rail & Engineering Ltd: (i) The company has received 2 orders worth Rs1313.6mn for manufacturing and supply of ACT-1 wagon alongwith 1 BVCM wagon and supply of 4 rakes of BFNS22.9 wagons alongwith 4 BVCM wagons, (ii) The company has received an order worth Rs278.2mn from Hindalco Industries for supply of 1 BTAP rake alongwith 1 brake van.

ICICI Bank Ltd: RBI has approved LIC to acquire upto 9.99% stake of the paid -up share capital or voting rights in the Bank within one year from the date of RBI approval letter, failing which RBI approval shall stand cancelled.

Container Corporation of India Ltd: The company has received order worth Rs890mn for the supply of 12 rakes of BLSS wagons with brake van type BVCM.

Alembic Pharmaceuticals Ltd: (i) The company has incorporated a WoS Alembic Pharmaceuticals Global FZCO in the UAE for a cash consideration of 100 shares of AED1000 each, (ii) The company has successfully completed an unannounced onsite bioequivalence inspection conducted by the USFDA (from 31st Aug-10th Sept'26) at the company's facility located in Vadodara with no Form 483 observations.

Metropolis Healthcare Ltd: Metropolis Quality Solutions Pvt. Ltd (WoS) has entered into a share subscription agreement with Medsource Ozone Biomedicals Pvt. Ltd and Dr. Puneet Kumar Nigam wherein the respective entities would invest Rs11mn and Rs1.6mn in MQSPL.

Max Healthcare Institute Ltd: The company has received a communication from KHL confirming the allotment of 5,021,212 equity shares on a rights basis. Pursuant to the aforesaid allotment, the company's shareholding in KHL has increased from ~58.28% to ~66.15% and KHL continues to remain a subsidiary of the company.

Mankind Pharma Ltd: The members of BSVL have accorded their approval for undertaking voluntary liquidation of BSVL (subject to approval of the creditors of BSVL in terms of the provisions of the IBC).

Alkem Laboratories Ltd: The company has announced launch of Renocia Exo, a next-generation hair regeneration therapy developed to support the health and vitality of the hair follicle through a comprehensive scientific approach.

Sun Pharmaceutical Industries Ltd: Sun Pharma Global Treasury Centre IFSC Ltd has been incorporated on 08th Sept'26 as an indirect WoS of the company in the International Financial Services Centre at Gujarat.

Indegene Ltd: The merger of Indegene Healthcare Germany GmbH with Trilogy Writing & Consulting GmbH became effective on 09th Sept'26 and consequent to the effectiveness of the merger, Indegene Healthcare Germany GmbH ceased to exist as a separate legal entity and Trilogy Writing & Consulting GmbH became the surviving entity.

Shilpa Medicare Ltd: The SEC has issued final approval for grant of marketing authorization for OERIS (Ondansetron ER Injection, 100 mg/mL); designed to be the world's first extended release ondansetron injectable formulation. OERIS will be launched in India and enjoys patent protection in India until 2039.

The Week That Went By:

Rising crude oil prices and higher bond yields weighed on market sentiment, pushing the Index lower throughout the week. It eventually settled at 23,398.10, down 499.60 points. Except for Pharma and Defence, all sectors ended in negative territory, with Realty and IT emerging as the major laggards. The broader market remained relatively resilient, although the Midcap and Smallcap indices also closed lower, declining 1.40% and 0.94%, respectively.

Nifty50=23,398.10 **Sensex30=74,781.76** **Nifty Midcap 100=62,197.20** **Nifty Smallcap100=19,906.30**

HIGHLIGHTS OF THE WEEK 07 Sept 2026-11 Sept 2026

NIFTY (WEEKLY)

BANK NIFTY (WEEKLY)



MARKET OUTLOOK

Nifty50 corrected more than 1,500 points, or 6.20%, from its August high and is currently trading near the strong base of June i.e., 23,100-23,250, which is expected to act as a significant support zone. On the daily chart, RSI is already in oversold territory, suggesting the possibility of a rebound. The 23,550-23,625 zone remains the primary resistance area, while 23,230 is likely to provide support. **BankNifty** defended its previous swing support at 56,030 and reversed to form a bullish candle, converting it into a strong support level. The nearest resistance is placed at 57,200. The **Pharma sector** continues to form a series of higher highs and higher lows following the symmetrical triangle breakout, indicating a strong uptrend. A buy on dips strategy may be considered. In contrast, the **Realty sector** formed a strong bearish candle and breached its consolidation phase on the downside. Since it is trading near the previous swing high and 200DMA, next week's price action will be crucial in determining whether the trend reverses or continues. Within the **Capital Market Index**, we remain positive on BSE and MCX and have added Motilal Oswal to our watchlist. The **FMCG segment** remains firmly under bearish pressure, and we advise staying away from the sector. **The coming week is eventful, with domestic releases such as CPI and WPI inflation data, and FED meeting. The movements in crude oil prices are likely to influence market direction significantly.**

HIGHLIGHTS OF THE WEEK 07 Sept 2026-11 Sept 2026

NIFTY 50 COMPONENTS (WEEKLY PERFORMANCE)

Adani Enterprises	4.15%	HDFC Life	(3.00%)	Reliance	(4.88%)
Adani Ports	3.36%	Hindalco	(2.92%)	SBI Life	(5.09%)
Apollo Hospital	2.15%	HUL	(2.35%)	SBIN	(2.01%)
Asian Paints	(2.17%)	ICICI Bank	(3.08%)	ShriRam Finance	(1.19%)
Axis Bank	(2.12%)	Indigo	(0.08%)	Sun Pharma	(3.11%)
Bajaj Auto	(2.02%)	INFY	(8.17%)	Tata Consumer	(1.88%)
Bajaj Finserv	(2.87%)	ITC	(1.61%)	Tata Steel	(3.07%)
Bajaj Finance	(2.45%)	JioFin	(4.01%)	TCS	(4.48%)
BEL	(0.25%)	JSW Steel	(4.53%)	Tech Mahindra	(3.50%)
Bharti Airtel	(0.48%)	Kotak Bank	(1.30%)	TITAN	(0.21%)
Cipla	(1.37%)	LT	(0.84%)	TMPV	(3.34%)
Coal India	2.66%	M&M	(1.99%)	Trent	(1.77%)
Dr. Reddy's Labs	1.26%	Maruti	(2.32%)	UltraTech	(3.58%)
Eicher Motors	(1.32%)	Max Healthcare	5.37%	Wipro	(5.10%)
Eternal	0.23%	Nestle India	(1.93%)		
Grasim	(1.21%)	NTPC	0.27%		
HCL Tech	(6.75%)	ONGC	(0.92%)		
HDFC Bank	(0.54%)	PowerGrid	1.17%		

SECTORAL PERFORMANCE



HIGHLIGHTS OF THE WEEK 07 Sept 2026-11 Sept 2026

SECTORAL GAINER

Despite the weakness in the Frontline Index, the **Pharma segment** remained resilient, ending the week in positive territory. Performance within the sector was mixed, with **Laurus Labs (+7.01%)** and **Wockhardt Pharma (+3.92%)** emerging as the top performers, while **Sun Pharma (-3.11%)** and **Abbott India (-2.11%)** were the major laggards. As shown in the chart, the sector has been forming a series of higher highs and higher lows following a symmetrical triangle breakout, indicating a strong uptrend. A buy-on-dips strategy may therefore be appropriate.

SECTORAL LOSER

The **Realty segment** lagged significantly, declining 6.54% during the week. All the counters came under pressure, with **Godrej Properties (-11.81%) and Lodha (-8.60%)** witnessing the sharpest declines, followed by **Brigade (-7.35%)** and **Oberoi Realty (-7.17%).** As shown in the chart, the sector formed a strong bearish candle and broke below its consolidation range. On the daily chart, it is trading near the previous swing high, which coincides with the 200DMA. The coming week's price action should provide clarity on whether the trend will reverse or continue.

HIGHLIGHTS OF THE WEEK 07 Sept 2026-11 Sept 2026

DISCLAIMERS AND DISCLOSURES-

Progressive Share Brokers Pvt. Ltd. and its affiliates are a full-service, brokerage and financing group. Progressive Share Brokers Pvt. Ltd. (PSBPL) along with its affiliates are participants in virtually all securities trading markets in India. PSBPL started its operation on the National Stock Exchange (NSE) in 1996. PSBPL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE) for its stock broking services and is Depository Participant with Central Depository Services Limited (CDSL) and is a member of Association of Mutual Funds of India (AMFI) for distribution of financial products.

PSBPL is SEBI registered Research Analyst under SEBI (Research Analysts) Regulations, 2014 with SEBI Registration No. INH000000859/Research Analyst BSE Enlistment No. 5049. PSBPL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years. PSBPL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

PSBPL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Progressive Share Brokers Pvt. Ltd. (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company (s) covered in this report-:

· PSBPL or its associates financial interest in the subject company: NO

· Research Analyst (s) or his/her relative's financial interest in the subject company: NO

· PSBPL or its associates and Research Analyst or his/her relative's does not have any material conflict of interest in the subject company. The research Analyst or research entity (PSBPL) has not been engaged in market making activity for the subject company.

· PSBPL or its associates actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO

· Research Analyst or his/her relatives have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO

· PSBPL or its associates may have received any compensation including for brokerage services from the subject company in the past 12 months. PSBPL or its associates may have received compensation for products or services other than brokerage services from the subject company in the past 12 months. PSBPL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Subject Company may have been client of PSBPL or its associates during twelve months preceding the date of distribution of the research report and PSBPL may have co-managed public offering of securities for the subject company in the past twelve months.

· The research analyst has served as officer, director or employee of the subject company: NO

· Registration granted by SEBI and certification from NISM is in no way guarantee performance of the intermediary or provide any assurance of returns to investors

PSBPL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our sales people, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses (if any) may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution publication, availability or use would be contrary to law or regulation or which would subject PSBPL or its group companies to any registration or licensing requirement within such jurisdiction. If this document is sent or has reached any individual in such country, especially, USA, the same may be ignored. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of PSBPL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of PSBPL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read “Risk Disclosure Document for Capital Market and Derivatives Segments” as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

Terms & Conditions:

This report has been prepared by PSBPL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of PSBPL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and its at discretion of the clients to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. PSBPL will not treat recipients as customers by virtue of their receiving this report.

Registered Office Address:

Progressive Share Brokers Pvt. Ltd,

122-124, Laxmi Plaza, Laxmi Indl Estate,

New Link Rd, Andheri West,

Mumbai-400053, Maharashtra

www.progressiveshares.com | Contact No.:022-40777500

Compliance Officer:

Ms. Mamatha Poojari,

Email: compliance@progressiveshares.com,

Contact No.:022-40777500

Grievance Officer:
Email: grievancecell@progressiveshares.com